Artemether/lumefantrine in the treatment of uncomplicated falciparum malaria
- 13 December 2006
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Pharmacotherapy
- Vol. 8 (1), 75-94
- https://doi.org/10.1517/14656566.8.1.75
Abstract
At present, artemether/lumefantrine (AL) is the only fixed-dose artemisinin-based combination therapy recommended and pre-qualified by WHO for the treatment of uncomplicated malaria caused by Plasmodium falciparum. It has been shown to be effective both in sub-Saharan Africa and in areas with multi-drug resistant P. falciparum in southeast Asia. It is currently recommended as first-line treatment for uncomplicated malaria in several countries. However, AL has a complex treatment regimen and the issues of adherence to treatment with AL by adult patients and real-life effectiveness in resource-poor settings will be critical in determining its useful therapeutic life, especially in Africa, where the major burden of malaria is felt. There are also issues of safety of the artemisinin derivatives, including AL, which will need to be monitored as their use in resource-poor settings becomes more widespread. There are limited pharmacokinetic studies of AL in African patients, and the relationship between plasma drug concentration and efficacy in these patients is unknown. Moreover, the effects of factors such as concurrently administered drugs, malnutrition and co-infections with HIV and helminths in malaria patients are not well understood. These will need to be addressed, although a few studies on possible drug–drug interactions with commonly used drugs, such as quinine, mefloquine and ketoconazole, have been reported. This review focuses on the status of clinical pharmacology, efficacy and real-life effectiveness of AL under a variety of settings, and highlights some of the challenges that face policy makers during the deployment of AL, especially in Africa, with regards to ensuring that those who most need this therapy will not be denied access due to official inefficiency in procurement and distribution processes.Keywords
This publication has 86 references indexed in Scilit:
- Feasibility and acceptability of the use of artemether‐lumefantrine in the home management of uncomplicated malaria in children 6–59 months old in GhanaTropical Medicine & International Health, 2006
- A meta-analysis of the association between adherence to drug therapy and mortalityBMJ, 2006
- Pregnancy-Related Effects on Nelfinavir-M8 Pharmacokinetics: a Population Study with 133 WomenAntimicrobial Agents and Chemotherapy, 2006
- Reduction of Malaria Transmission to Anopheles Mosquitoes with a Six-Dose Regimen of Co-ArtemetherPLoS Medicine, 2005
- Artemisinin derivatives: toxic for laboratory animals, safe for humans?Toxicology Letters, 2004
- Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and womenPharmacogenetics, 2003
- Clinical Pharmacokinetics and Pharmacodynamics of Artemether-LumefantrineClinical Pharmacokinetics, 1999
- Strategies for the prevention of antimalarial drug resistance: Rationale for combination chemotherapy for malariaParasitology Today, 1996
- The Safety of Antimalarial Drugs in PregnancyDrug Safety, 1996
- The toxicity of artemisinin and related compounds on neuronal and glial cells in cultureChemico-Biological Interactions, 1995